Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

65.62
-0.2900-0.44%
Post-market: 65.620.00000.00%19:30 EDT
Volume:1.72M
Turnover:113.77M
Market Cap:9.12B
PE:-9.14
High:67.27
Open:65.73
Low:65.30
Close:65.91
52wk High:88.31
52wk Low:53.61
Shares:139.02M
Float Shares:138.02M
Volume Ratio:0.76
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-52.58
PE(LYR):-10.03

Loading ...

Evercore ISI Remains a Buy on Cytokinetics (CYTK)

TIPRANKS
·
Aug 31

Cytokinetics Price Target Maintained with a $140.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

Cytokinetics (CYTK) Extends Aficamten Phase 3 Data, Is It Still 33% Below Fair Value?

Simply Wall St.
·
Aug 31

RBC Capital Sticks to Their Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
Aug 31

Cytokinetics announces results from ACACIA-HCM, MAPLE-HCM

TIPRANKS
·
Aug 31

Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCM - Has The Bull Case Changed?

Simply Wall St.
·
Aug 30

Cytokinetics Posts MAPLE-HCM Presentation on Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy

Reuters
·
Aug 29

Cytokinetics Announces Additional Results from Acacia-HCM and Maple-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (Esc) Congress 2026

THOMSON REUTERS
·
Aug 29

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

GlobeNewswire
·
Aug 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 29

Movement Alert|Cytokinetics Intraday Decline 6.03%, Shares Retreat Despite Positive Phase 3 Trial Data Presentation at ESC Congress

Market Focus
·
Aug 28

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28

U.S. Stocks on the MOVE-Cytokinetics, Moderna, Ulta Beauty

Reuters
·
Aug 28

Cytokinetics Phase 3 Trial Shows Aficamten Improves Heart Disease Symptoms

MT Newswires Live
·
Aug 28

Movement Alert|Cytokinetics Rises 6.74% in Pre-Market Trading, Acacia-HCM Results Published in NEJM with Q4 FDA Submission Planned

Market Focus
·
Aug 28

Cytokinetics Shares up 1.4% Premarket After Co Presents New Late-Stage Data for Heart Drug at European Society of Cardiology

THOMSON REUTERS
·
Aug 28

Cytokinetics to File FDA sNDA for Aficamten in Non-Obstructive HCM in Q4 2026

Reuters
·
Aug 28

Cytokinetics Plans to Submit Supplemental NDA to U.S. FDA for Aficamten in Q4 2026

Reuters
·
Aug 28

Cytokinetics Announces Positive Results from Acacia-HCM Presented in Hot Line Session at the European Society of Cardiology (Esc) Congress 2026 and Published in the New England Journal of Medicine

THOMSON REUTERS
·
Aug 28

Cytokinetics: Plans to Submit Supplemental Nda to U.S. FDA for Aficamten for Treatment of Adult Patients with Symptomatic Nhcm in Q4

THOMSON REUTERS
·
Aug 28